Investigational

15 papers3 directions
Investigational is a research venue active between 2005 and 2025 that focuses on the application of computational and statistical methods to clinical medicine and pharmacology. The venue is known for its emphasis on histopathological characterization for definitive clinical diagnosis and the use of multi-modal integration to resolve diagnostic mimicry. Research published here frequently addresses technical challenges in the field, such as statistical power limitations when analyzing rare clinical outcomes and the complexities of metabolic interference and Cytochrome P450 bottlenecks. The venue’s corpus includes studies on the clinical features and prognosis of drug-induced conditions, such as immune encephalitis and pulmonary inflammation following targeted therapies. It also features research on the mechanisms of small molecule inhibitors, the metabolic profiles of poly(ADP-ribose) polymerase inhibitors, and the use of microRNA-mRNA integrated analysis to explore treatment effects in oncology. These works often involve the evaluation of absorption, distribution, metabolism, and excretion (ADME) of therapeutic compounds in patients with advanced solid tumors. Investigational serves a specialized community of researchers, including prolific authors such as Jürgen Sonnemann, Hiroaki Suga, and Ikuo Kashiwakura. By providing a platform for research into DNA vaccine potency and the inhibitory effects of compounds like esomeprazole on cancer metastasis, the venue facilitates the exchange of data-driven insights between the fields of pathology, oncology, and computational biology.

Papers by Year

2025 1
2022 2
2020 1
2019 1
2017 2
2015 1
2014 1
2013 1
2011 2
2010 2
2005 1

Top Research Directions

Research directions most represented by papers from this venue.

Mechanisms of Metabolic Drug-Drug Interactions 1
Overcoming the Pharmacokinetic Characterization Gap 1
Overcoming Systemic Toxicity in Cancer Immunotherapy 1

Papers

TitleYear
Clinical features, treatment, and prognosis of nivolumab induced immune encephalitis2025
A small molecule inhibitor of VSIG-8 prevents its binding to VISTA2022
Pulmonary granulomatous inflammation after ceritinib treatment in advanced ALK-rearranged pulmonary adenocarcinoma2022
Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis2020
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors2019
Crucial microRNAs and genes in metformin’s anti-pancreatic cancer effect explored by microRNA-mRNA integrated analysis2017
The sirtuin 1/2 inhibitor tenovin-1 induces a nonlinear apoptosis-inducing factor-dependent cell death in a p53 null Ewing’s sarcoma cell line2017
Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency2015
Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early re2014
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study2013
Caspase-independent apoptosis induction of quorum-sensing autoinducer analogs against chronic myeloid leukemia K5622011
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma2011
Functional properties of synthetic N-acyl-L-homoserine lactone analogs of quorum-sensing gram-negative bacteria on the growth of human oral squamous carcinoma cells2010
Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression2010
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines2005